According to the research report, the global asthma and COPD drugs market size is expected to touch USD 56.7 Billion by 2030, from USD 37.22 Billion in 2022, growing with a significant CAGR of 5.4% from 2022 to 2030.
The asthma and COPD drugs report offers a
comprehensive study of the current state expected at the major drivers, market
strategies, and key vendors’ growth. The report presents energetic visions to
conclude and study the market size, market hopes, and competitive surroundings.
The research also focuses on the important achievements of the market, research
& development, and regional growth of the leading competitors operating in
the market. The current trends of the global asthma and COPD drugs in
conjunction with the geographical landscape of this vertical have also been
included in this report.
The report offers intricate dynamics about
different aspects of the global asthma and COPD drugs market, which aids
companies operating in the market in making strategic development decisions.
The study also elaborates on significant changes that are highly anticipated to
configure growth of the global asthma and COPD drugs during the forecast
period. It also includes a key indicator assessment that highlights growth
prospects of this market and estimates statistics related to growth of the
market in terms of value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1711
| Report Coverage | Details |
| Market Size by 2030 | USD 56.7 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 5.4% |
| Largest Market | North America |
| Fastest Growing Market | Europe |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Diseases, Medication Class, Distribution Channel, Geography |
This study covers a detailed segmentation
of the global asthma and COPD drugs market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global asthma and COPD drugs market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co. Inc
- Grifols S.A.
- Novartis AG
- Cipla Inc.
- Abbott
- Astellas Pharma
- Hoffmann-La Roche Ltd
- Glenmark Pharmaceuticals
Market Segmentation
- Asthma
- COPD
By Medication Class
- Combination Drugs
- Bronchodilators
- Inhaled Corticosteroids (ICS)
- Short Acting Beta Agonists (SABA)
- Long Acting Beta Agonists (LABA)
- Leukotriene Antagonists (LTA)
- Anticholinergics
- Anti-Inflammatories
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global asthma and COPD drugs report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global asthma and COPD drugs market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma and COPD Drugs Market
5.1. COVID-19 Landscape: Asthma and COPD Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma and COPD Drugs Market, By Diseases
8.1. Asthma and COPD Drugs Market, by Diseases Type, 2022-2030
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. COPD
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Asthma and COPD Drugs Market, By Medication Class
9.1. Asthma and COPD Drugs Market, by Medication Class, 2022-2030
9.1.1. Combination Drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bronchodilators
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhaled Corticosteroids (ICS)
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Short Acting Beta Agonists (SABA)
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Long Acting Beta Agonists (LABA)
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Leukotriene Antagonists (LTA)
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Anticholinergics
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Asthma and COPD Drugs Market, By Distribution Channel
10.1. Asthma and COPD Drugs Market, by Distribution Channel, 2022-2030
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Drug Stores
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Asthma and COPD Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Teva Pharmaceutical Industries Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co. Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Grifols S.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Cipla Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Abbott
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hoffmann-La Roche Ltd
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Glenmark Pharmaceuticals
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments